シンポジウム

Symposia

Friday, 22 March 11:00 ～ 12:05 / 14:45 ～ 17:40
Plenary Lecture: Room C, International Conference Hall, Makuhari Messe
Invited Poster Presentation: Room PO, International Exhibition Hall 8, Makuhari Messe
第 5 回国際創薬シンポジウム ISMS
5th International Symposium for Medicinal Sciences
11:00 ～ 11:05
Opening Remark 

Chairman: Akira OTAKA（Tokushima University）

11:05 ～ 12:05
Plenary Lecture 1 ISMS-PL01

Chairman: Yoshio HAYASHI（Tokyo University of Pharmacy and Life Sciences）

Attacking the Cell Surfaceome in Cancer
James A. WELLS（Department of Pharmaceutical Chemistry, University of California）

14:45 ～ 15:45
Plenary Lecture 2 ISMS-PL02

Chairman: Daisuke TANAKA（Exscientia Ltd.）The AI Revolution in Drug Discovery
Andrew L. HOPKINS（Exscientia Ltd.）

16:00 ～ 17:40
Invited Poster Presentation
Odd Number: 16:00 ～ 16:50
Even Number: 16:50 ～ 17:40
ISMS-IP01

Clinical Evidence-based Drug Repositioning and Target Discovery○ Shuji KANEKO1, Takuya NAGASHIMA1（1Department of Molecular Pharmacology, Graduate Schoolof Pharmaceutical Sciences, Kyoto University）

ISMS-IP02

New Insights for Drug Repositioning: the Integrative Approach○ Lili MAO1, Mai FUJIMOTO2, Kouichi HOSOMI2, Mitsutaka TAKADA2, Juran KATO1
1

2（ GEXVal Inc., Division of Clinical Drug Informatics, School of Pharmacy, Kindai University）

ISMS-IP03

Development of Acyl Transfer-based Chemical Biology Tools for Purification/Selective
Labeling of Target Proteins○ Akira SHIGENAGA1, Takuya MORISAKI1, Taiki KOHIKI1, Masaya DENDA1, 
Tsubasa INOKUMA1, Akira OTAKA1（1Institute of Biomedical Sciences and Graduate School of
Pharmaceutical Sciences, Tokushima University）

ISMS-IP04

Selective Degradation of Splicing Factor CAPERα by Anticancer Sulfonamides○ Taisuke UEHARA1, Yukinori MINOSHIMA1, Koji SAGANE1, Naoko HATA SUGI1, 
Kaoru OGAWA MITSUHASHI1, Noboru YAMAMOTO1, Hiroshi KAMIYAMA1, 
Kentaro TAKAHASHI1, Yoshihiko KOTAKE1, Mai UESUGI1, Akira YOKOI1, 
Atsushi INOUE1, Miyuki MABUCHI2, Akito TANAKA2, Takashi OWA1（1Eisai Co., Ltd., 2School of
Pharmacy, Hyogo University of Health Science）

ISMS-IP05

Target-selective Degradation of Intracellular Molecules via Autophagy○ Daiki TAKAHASHI1, Jun MORIYAMA1, Erika MIKI1, Tomoe NAKAMURA1, 
Ayami SATO1, Kaori ITTO-NAKAMA1, Hirokazu ARIMOTO1（1Graduate School of Life Sciences,
Tohoku University）– 26 –ISMS-IP06

Investigation of the Chemical Space for Brain Penetrable, Carboxylic Acid-containing
Compounds: Expanding the Area Available for CNS Drug Discovery○ Yoshiaki OHASHI1（1Medicinal Chemistry, Neurology Tsukuba Research Department, Discovery, Medicine
Creation, Neurology Business Group, Eisai Co., Lid.）

ISMS-IP07

Interaction Analysis between MDM2 and Its Inhibitors by Fragment Molecular Orbital
Method○ Norihito KAWASHITA1, Naoto MOTOYAMA2, Tian YU-SHI2, Hirotomo MORIWAKI2,
Tatsuya TAKAGI2（1Faculty of Science and Engineering, Kindai University, 2Graduate School of Pharmaceutical
Sciences, Osaka University）

ISMS-IP08
ISMS-IP09

SEEDSUPPLY Contributes to Maximizing the Values of Small Molecule Drug Discovery○ Takashi MOTOYAJI1（1SEEDSUPPLY INC.）
A Prediction Framework for Drug Discovery Using Graph Convolutional Networks○ Ryosuke KOJIMA1（1Department of Biomedical Data Intelligence, Graduate School of Medicine, Kyoto
University）

ISMS-IP10

Autodesign – an Automated Drug Design by Using Molecular Simulation Data ofProtein-ligand Systems○ Hironori KOKUBO1, Naoki MIYAMOTO1, Yoshi NARA1, Sachiko ITONO1（1Axcelead Drug
Discovery Partners, Inc.）

ISMS-IP11

Generation of Chemical Structures with a Desired Pharmacophore Using Deep
Reinforcement Learning
3 1
Institute○ Atsushi YOSHIMORI1, Enzo KAWASAKI2, Chisato KANAI2, Tomohiko TASAKA（
2

3

for Theoretical Medicine, Inc., Kyoto Constella Technologies Co., Ltd, Affinity Science Corp.）

ISMS-IP12
ISMS-IP13

Chemical Data Science for Drug Design: New Development of the KY-methods in Big
Data Era○ Kohtaro YUTA1（1In Silico Data, Ltd.）
Development of Fluorescent Probes for Exopeptidases for Realizing Novel Medical
Imaging○ Yugo KURIKI1, Mako KAMIYA2,3, Toru KOMATSU1, Yasuteru URANO1,2,4（1Grad. Sch.
23

4

Pharm. Sci., Grad. Sch. Med., The Univ. of Tokyo, JST PRESTO, AMED CREST）

ISMS-IP14

Artificial Chemical Transformation of Amyloid Peptide by Catalytic Photo-Oxygenation○ Youhei SOHMA1, Jizhi NI1, Atsuhiko TANIGUCHI1,2, Shuta OZAWA1, Yukiko HORI1,
Taisuke TOMITA1, Motomu KANAI1（1Graduate School of Pharmaceutical Sciences, The University of
2Tokyo, Tokyo University of Pharmaceutical and Life Sciences）

ISMS-IP15
ISMS-IP16
ISMS-IP17
ISMS-IP18

Potential of Imaging Mass Spectrometry in Neurotransmitter-driven Drug Discovery○ Kenichi WATANABE1, Jun TADANO1, Toichiro YAMADA1, Tetsuya NAKAGAWA1,
Izuru MIYAWAKI1（1Sumitomo Dainippon Pharma Co.,Ltd.）
Screening of Food Materials and Drugs that Can Suppress Cardio Sudden Death by
Lipid Peroxidation Using Heart Specific GPx4 KO Mice
○ Tomoko KOUMURA1, Hirotaka IMAI1（1School of Pharmaceutical Sciences, Kitasato University）
Long-Lasting Effect of Allergen-Specific Sublingual Immunotherapy is Dose andDuration Dependent in a Murine Allergic Rhinitis Model○ Soichi TOFUKUJI1（1Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd.）
Recent Progress in the Development of Microphysiological Systems and Their
Implementation at Astellas○ Kazuhiro TETSUKA1, Masato OHBUCHI1, Tetsuhiro KAWABE1, Takayuki GOTO1,
Fumiko KIYONAGA1, Kaori TAKAMA1, Shunji YAMAZAKI1, Akira FUJIMORI1
1（ Drug Discovery Research, Astellas Pharma Inc.）

ISMS-IP19

Docetaxel might be Preferable Combination Partner for Immunotherapy○ Miya HARUNA1,2, Yoko YAMAMOTO2, Michinari HIRATA1,2, Kumiko GOTO1,2, Takanori KANAZAWA1, Kayoko MAEKAWA2, Kota IWAHORI2, Hisashi WADA2（1Shionogi
2Co., Ltd., Department of Clinical Research in Tumor Immunology of Osaka University）– 27 –ISMS-IP20

Enhanced Anti-tumor Effects of IFN- γ Producing Bifidobacterium in Combination with
PD-1 Antibody in a Syngeneic Murine Model○ Satoshi KOBAYASHI1, Yuji SEKI1, Koichiro SHIOYA1, Shiro KATAOKA1, Li WANG1,
Yuko SHIMATANI1, Minoru FUJIMORI2, Shun’ichiro TANIGUCHI3, Takaaki NAKAMURA1
1

2（ Anaeropharma Science, Inc., Department of Breast Surgery, Tokyo Medical University Ibaraki Medical Center,3
Department of Comprehensive Cancer Therapy, Shinshu University School of Medicine）

ISMS-IP21

Genetically Modified Adipocytes, GMAC, for Regenerative Cell Medicine and Gene
Therapy○ Masayuki KURODA1, Koutaro YOKOTE2, Yasushi SAITO3, Masayuki ASO4（1Center for
2

Advanced Medicine, Chiba University, Department of Clinical Cell Biology and Medicine, Graduate School of34
Medicine, Chiba University, Superintendent of the hospital bureau, City hall of Chiba, CellGenTech, Inc.）

ISMS-IP22

Engineered Bacterial Cancer Therapy Using Bifidobacterium Secreting Agonistic
Anti-4-1BB scFv in the Mouse Model○ Tomio MATSUMURA1, Koichiro SHIOYA1, Yasuyoshi KANARI1, Yuko SHIMATANI1,
Shiro KATAOKA1, Shun’ichiro TANIGUCHI2, Takaaki NAKAMURA1（1Anaeropharma Science,
2Inc., Department of Comprehensive Cancer Therapy, Shinshu University School of Medicine）

ISMS-IP23
ISMS-IP24

Selenoprotein P-neutralizing Antibodies Improve Insulin Secretion in Type 2 Diabetes
Mouse Models○ Xinying YE1, Yoshiro SAITO1（1Graduate School of Pharmaceutical Sciences, Tohoku University）
Targeting Cancer Stromal Fibrin with Antibody-Drug Conjugate in Pancreatic Tumor
Mouse Model○ Kaori HAYASHI1, Hirobumi FUCHIGAMI1, Makoto WAKATSUKI2, 
Yasuhiro MATSUMURA1（1Division of Developmental Therapeutics, National Cancer Center Exploratory2

Oncology Research & Clinical Trial Center, Department of Integrated Bioscience, Graduate School of Frontier
Sciences, The University of Tokyo）

ISMS-IP25

ADC Payload and Linker Chemistry-Dolastatin 10 Analogues and Non-Cleavable
Linkers○ Michinori AKAIWA1,2, Tioga MARTIN2, Brian A. MENDELSOHN2（1Modality Research Labs.
2

Drug Discovery Research, Astellas Pharma Inc., Agensys Inc.）

ISMS-IP26

A Novel Strategy for Destabilization of Oncogenic Fusion Protein BCR-ABL to Inhibit
Growth of CML○ Norihito SHIBATA1, Nobumichi OHOKA1, Mikihiko NAITO1（1National Institute of Health
Sciences, Division of Molecular Target and Gene Therapy Products）

ISMS-IP27

Inhibition of Influenza A (H7N9) Virus Replication by the Novel Cap-dependent
Endonuclease Inhibitor Baloxavir Marboxil○ Keiichi TANIGUCHI1,2, Yoshinori ANDO1, Haruaki NOBORI1,2, Shinsuke TOBA1,2, Takeshi NOSHI1, Masanori KOBAYASHI1,3, Makoto KAWAI1, Ryu YOSHIDA1, 
Akihiko SATO1,2, Takao SHISHIDO1, Akira NAITO1, Keita MATSUNO2,4, Masatoshi OKAMATSU2, Yoshihiro SAKODA2,4, Hiroshi KIDA2,4（1Shionogi & Co., Ltd., 2Hokkaido
3

4

University, Gifu University, Global Station for Zoonosis Control, Global Institution for Collaborative Research and
Education (GI-CoRE)）

ISMS-IP28

Discovery of TA-8995 (obicetrapib) as a CETP Inhibitor○ Norimitsu HAYASHI1, Hitoshi KUBOTA1, Yoshinori NAKAMURA1, Yasuo YAMAMOTO1,
Masakatsu SUGAHARA1, Takanori HIGASHIJIMA1, Mariko OOI1, Kozo OKA1
1（ Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation）

ISMS-IP29

Drug Discovery of Novel Aminoglycoside Antibiotics Active Against MultidrugResistant Gram-Negative Bacteria○ Yasunari OTSUKA1, Eijiro UMEMURA1, Yoshiaki TAKAHASHI1, Yukimi TAKAMIYA1,
Teruhisa ISHIBASHI1, Chigusa HAYASHI1, Masayuki IGARASHI1, Masakatsu SHIBASAKI1
1（ Institute of Microbial Chemistry (BIKAKEN) ）– 28 –ISMS-IP30

Structure Activity Relationship Study of Naturally Occurring Cyclodepsipeptide
Destruxins○ Masahito YOSHIDA1, Hiroshi SATO2,3, Gen KONNO2, Yuna NIWA4, Mika TOMIDA4,
Hiroshi NAKAGAWA4, Takayuki DOI2（1Faculty of Pure and Applied Sciences, University of Tsukuba,
2

3

Graduate School of Pharmaceutical Sciences, Tohoku University, Mitsubishi Tanabe Pharma Corporation,
Department of Applied Biological Chemistry, Chubu University）

4

ISMS-IP31

Design Strategy for Potent Dipeptidyl Peptidase IV (DPP-4) Inhibitors by Incorporating
Salt Bridge Formation with Lys554○ Hironobu MAEZAKI1*, Michiko TAWADA1, Tohru YAMASHITA1, Yoshihiro BANNO1*,
Yasufumi MIYAMOTO1, Yoshio YAMAMOTO1, Koji IKEDO1, Takuo KOSAKA1, 
Shigetoshi TSUBOTANI1, Akiyoshi TANI1, Tomoko ASAKAWA1, Nobuhiro SUZUKI1, 
Satoru OI1（1Takeda Pharmaceutical Company Limited, *Present address: Axcelead Drug Discovery Partners,
Inc.）

ISMS-IP32

Discovery of a Dihydronaphthalene-Based Sphingosine-1-Phosphate (S1P) Receptor
Agonist: Ceralifimod (ONO-4641)○ Haruto KURATA1, Kensuke KUSUMI1, Kazuhiro OTSUKI1, Ryo SUZUKI1, 
Masakuni KURONO1, Takaki KOMIYA2, Hiroshi HAGIYA2, Hirotaka MIZUNO2, 
Hiroki SHIOYA2, Takeji ONO2, Yuka TAKADA2, Tatsuo MAEDA2, Norikazu MATSUNAGA3,
Tetsu KONDO3, Sachiko TOMINAGA3, Ken-ichi NUNOYA3, Hidekazu KIYOSHI4, 
Masaharu KOMENO4, Shinji NAKADE2, Hiromu HABASHITA1（1Medicinal Chemistry Research
2

3

4

Laboratories, Exploratory Research Laboratories, Pharmacokinetic Research Laboratories, Safety ResearchLaboratories, Ono Pharmaceutical Co., Ltd.）ISMS-IP33

Discovery of Clinical Candidate TAK-915, A Highly Potent, Selective, and BrainPenetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders○ Satoshi MIKAMI1（1Drug Discovery Chemistry Laboratories, Neuroscience Drug Discovery Unit, Research,
Takeda Pharmaceutical Company Limited）

ISMS-IP34

Development of Novel Bicyclic Pyrazoles as Potent and Selective ALK2 (R206H)
Inhibitors for the Treatment of Fibrodysplasia Ossificans Progressiva
Hirofumi YAMAMOTO1, Naoki SAKAI2, Satoshi OHTE3, ○ Katsuhiko SEKIMATA1,
Tomohiro SATO4, Takehisa MATSUMOTO2, Yoshifumi FUJII5, Noriko HANDA5, 
Hisami WATANABE2, Chiemi MISHIMA-TSUMAGARI2, Akiko TANAKA2, 
Teruki HONMA4, Yoshinobu HASHIZUME6, Shigeyuki YOKOYAMA5, Hiroshi TOMODA3,
Mikako SHIROUZU2, Kohei MIYAZONO7, Hiroo KOYAMA1（1RIKEN Center for Sustainable
2

Resource Science, Drug Discovery Chemistry Platform Unit, RIKEN Center for Biosystems Dynamics Research,
3
Drug Discovery Structural Biology Platform Unit, Kitasato University, Graduate School of Pharmaceutical Sciences,
4
RIKEN Center for Biosystems Dynamics Research, Drug Discovery Computational Chemistry Platform Unit,
5
6
RIKEN Systems and Structural Biology Center, Crystallographic Drug Discovery Platform Unit, RIKEN Program
7
for Drug Discovery and Medical Technology Platforms, The University of Tokyo, Graduate School of Medicine,
Department of Molecular Pathology）

ISMS-IP35

ISMS-IP36

Design, Synthesis and Evaluation of 8-(methylamino)-2-oxo-1,2-dihydroquinoline (MAOQ)
Derivatives as Novel DNA Gyrase and Topoisomerase IV Inhibitors○ Fumihito USHIYAMA1, Hideaki AMADA1, Takashi YOSHIZUMI1, Yasuhiro MIHARA1,
Tomoki TAKEUCHI1, Nozomi YAMAMOTO1, Junya YAMAGISHI1, Aiko MASUKO1, 
Kiyoko FUJITA1, Masashi MIMA1, Koichiro NAKANO1, Hirotoshi OKUMURA1, 
Hiroyuki SUGIYAMA1, Norikazu OHTAKE1（1Taisho Pharmaceutical Co., Ltd.）
Design, Synthesis and Evaluation of Novel Class of Orally Bioavailable eIF4A3-selective
Inhibitors○ Ryo MIZOJIRI1, Daisuke NAKATA1, Yoshihiko SATOH1, Daisuke MORISHITA1, 
Misa IWATANI-YOSHIHARA1, Yohei KOSUGI1, Mai KOSAKA1, Junpei TAKEDA1,
Shigekazu SASAKI1, Kazuaki TAKAMI1, Masahiro KAMAURA1, Shinobu SASAKI1, 
Ryosuke ARAI1, Douglas R. CARY1, Yasuhiro IMAEDA1（1Takeda Pharmaceutical Company Limited）– 29 –ISMS-IP37

Discovery, SAR and in vivo Effects of Novel Natriuretic Peptide Receptor A (NPR-A)
agonists○ Takehiko IWAKI1, Yuji NAKAMURA1, Taisaku TANAKA1, Yasuyuki OGAWA1, 
Osamu IWAMOTO1, Yamato SUZUKI1, Yoshihiko OKAMURA1, Yumi KAWASE1, 
Akira YAMAKI1, Makoto IWANAMI1, Yoshiaki OYAMA1, Takahiro NAGAYAMA1（1Daiichi
Sankyo CO., LTD.）

ISMS-IP38

Discovery of Orally Efficacious RORγ Inhibitors Composed of an Isoxazole Scaffold○ Masayuki KOTOKU1,3, Takaki MAEBA1, Shingo FUJIOKA1, Masahiro YOKOTA1,
Noriyoshi SEKI1, Keisuke ITO1, Yoshihiro SUWA1, Taku IKENOGAMI1, Kazuyuki HIRATA1,
Yoshiaki KATSUDA1, Naoki MIYAGAWA1, Kojo ARITA1, Kota ASAHINA1, 
Masato NOGUCHI1, Akihiro NOMURA1, Satoki DOI1, Tsuyoshi ADACHI1, Paul CROWE2,Haiyan TAO2, Scott THACHER2, Hiromasa HASHIMOTO1, Takayoshi SUZUKI3, 
Makoto SHIOZAKI1（1JAPAN TOBACCO INC. Central Pharmaceutical Research Institute, 2Orphagen
3

Pharmaceuticals, Graduate School of Medical Science, Kyoto Prefectural University of Medicine）

ISMS-IP39

Discovery of Potent, Orally Available, and Brain-Penetrating Receptor Interacting
Protein 1 (RIP1) Kinase Inhibitors: Analysis of Structure − Kinetic Relationships○ Masato YOSHIKAWA1（1Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company
Limited）

ISMS-IP40
ISMS-IP41

Estimating Efflux Transporter-mediated Disposition Using Transporter Gene Knockout
Rats○ Taiji MIYAKE1（1Discovery ADMET Dept., Research Div., Chugai Pharmaceutical Co., Ltd.）
Prediction of Human Distribution Volumes of Compounds in Various Elimination Phases
Using Physiologically Based PK Modeling and Experimental PK in Animals○ Hidetoshi SHIMIZU1, Kosuke YOSHIDA1, Tomohisa NAKADA1, Koki KOJIMA1, 
Akihito OGASAWARA1, Yoshinobu NAKAMARU1, Hiroshi YAMAZAKI2（1Mitsubishi Tanabe
2

Pharma Corporation, Showa Pharmaceutical University）

ISMS-IP42Supersaturated Transdermal Formulation Designed by Co-amorphous System○ Yuya HIRAKAWA1,2, Hiroshi UEDA1, Tetsuya MIYANO1, Noriho KAMIYA2, 
Masahiro GOTO2（1Research Laboratory for Development, Shionogi & Co., Ltd., 2Department of Applied
Chemistry, Kyushu University）

ISMS-IP43

Kilogram-Scale Synthesis of Esomeprazole and Related Proton Pump Inhibitors throughIron-Catalyzed Enantioselective Sulfoxidation○ Shigenobu NISHIGUCHI1, Takuhiro IZUMI1, Takayoshi KOUNO2, Junpei SUKEGAWA1,
Laurean ILIES3,4, Eiichi NAKAMURA4（1Towa Pharmaceutical Co., Ltd., 2Daichikasei Co., Ltd., 3RIKEN,
4Tokyo University）– 30 –